Russell Goodman is a Gastroenterology physician affiliated with Harvard University. OpenAlex indexes 62 publications with 5,532 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
75 Francis St
Boston, MA 021156110
Telephone
617-732-5500Registry record last updated 28 Nov 2016.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Madrigal PharmaceuticalsProgram year20251 payment
- INTERCEPT PHARMACEUTICALS, INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
67.1%Bile Acid26%Ursodiol100%Part D<11 patientsOsmotic Laxative23.3%Gavilyte-G100%Part D≥17 patients+ 1 more class in this area
Cardiovascular
17.8%Loop diuretic17.8%Furosemide100%Part D<11 patientsAnti-infectives
15.1%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor15.1%Entecavir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2016–2026 per NIH RePORTER. The latest:
- An NADH-ChREBP axis in fatty liver disease and dyslipidemia
Massachusetts General Hospital
FY2026$502,691R01DK134675 - An NADH-ChREBP axis in fatty liver disease and dyslipidemia
Massachusetts General Hospital
FY2025$471,860R01DK134675 - An NADH-ChREBP axis in fatty liver disease and dyslipidemia
Massachusetts General Hospital
FY2024$522,817R01DK134675
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Antin, MD
Harvard University
Sarah Fortune, MD
Harvard University
Elizabeth Buchbinder, MD
Harvard University
Ethan Lerner, MD
Harvard University
Charles Rice, MD
The Rockefeller University
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai
Kris Kowdley, MD
Washington State University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”